Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness

Glioblastoma is the most commonly malignant and aggressive brain tumor, with a high mortality rate. The role of the purine nucleotide adenosine and its interaction with its four subtypes receptors coupled to the different G proteins, A1, A2A, A2B, and A3, and its different physiological functions in...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-08, Vol.14 (16), p.4032
Main Authors: Bova, Valentina, Filippone, Alessia, Casili, Giovanna, Lanza, Marika, Campolo, Michela, Capra, Anna Paola, Repici, Alberto, Crupi, Lelio, Motta, Gianmarco, Colarossi, Cristina, Chisari, Giulia, Cuzzocrea, Salvatore, Esposito, Emanuela, Paterniti, Irene
Format: Article
Language:English
Subjects:
Adenosine
Alzheimer's disease
Angiogenesis
Blood vessels
Brain cancer
Brain tumors
Cancer
Cancer immunotherapy
Cancer therapies
Care and treatment
CD73 antigen
Chemotherapy
Disease management
Drug targeting
Drug therapy
Fibroblasts
Gene expression
Glioblastoma
Glioblastoma multiforme
Health aspects
Hypoxia
Immune system
Immunotherapy
Methods
Mortality
Mutation
Older people
Radiation
Review
Stem cells
Tumor microenvironment
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma is the most commonly malignant and aggressive brain tumor, with a high mortality rate. The role of the purine nucleotide adenosine and its interaction with its four subtypes receptors coupled to the different G proteins, A1, A2A, A2B, and A3, and its different physiological functions in different systems and organs, depending on the active receptor subtype, has been studied for years. Recently, several works have defined extracellular adenosine as a tumoral protector because of its accumulation in the tumor microenvironment. Its presence is due to both the interaction with the A2A receptor subtype and the increase in CD39 and CD73 gene expression induced by the hypoxic state. This fact has fueled preclinical and clinical research into the development of efficacious molecules acting on the adenosine pathway and blocking its accumulation. Given the success of anti-cancer immunotherapy, the new strategy is to develop selective A2A receptor antagonists that could competitively inhibit binding to its endogenous ligand, making them reliable candidates for the therapeutic management of brain tumors. Here, we focused on the efficacy of adenosine receptor antagonists and their enhancement in anti-cancer immunotherapy.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14164032